Winner of Pierre Delmas Prize announced at World Congress on Osteoporosis 2010

May 05, 2010

The prestigious Pierre Delmas Prize: An ESCEO-IOF/Servier Achievement Award was awarded today to Professor Pierre Jean Meunier, Professor Emeritus at the Claude Bernard University of Lyon, France.

This important new annual scientific award is named in honour of the late Pierre D. Delmas, the world renowned researcher and co-founder of the International Osteoporosis Foundation (IOF). The grant of 40,000 Euros, courtesy of Servier, is awarded to Professor Meunier in honour of his outstanding and major scientific contributions to the study of bone and mineral diseases.

In presenting the award, ESCEO President Professor Jean-Yves Reginster lauded Professor Meunier for his influential work in the field of osteoporosis and rheumatic diseases as well as his eminent role as a mentor and editor in the bone arena. "Indeed it is especially fitting that this award goes to Professor Meunier, as he was an early and influential mentor to the young Pierre Delmas," stated Professor Reginster.

Servier CEO Dr. Jean-Philippe Seta congratulated the winner and noted, "In sponsoring this Prize, Servier underlines its commitment to furthering advances in rheumatology and osteoporosis treatment."

Professor Meunier has published more than 370 scientific manuscripts and books, and is recipient of several important awards including the IBMS John Haddad Prize and the ASBMR Frederic C. Bartter Award. He was named Officer of the Ordre des Palmes Académiques, awarded by the French government for services in education. Among many notable positions, Professor Meunier was the President of the European Foundation for Osteoporosis (from 1990-1996), Founder and Director of an INSERM Research Unit on the pathology of calcified tissue, Founding Board Member of the International Osteoporosis Foundation and Founder and Honorary President of the Groupe de Recherche et d'Informations sur les Ostéoporoses (GRIO).

The award was presented at the opening ceremony of the World Congress on Osteoporosis 2010 (IOF WCO-ECCEO10) in Florence, Italy which continues on to May 8, 2010.
-end-
ABOUT ESCEO

The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of osteoporosis and osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception. www.esceo.org

ABOUT IOF

The International Osteoporosis Foundation (IOF) is a nongovernmental umbrella organization dedicated to the worldwide fight against osteoporosis, the disease known as "the silent epidemic". IOF's members - committees of scientific researchers, patient, medical and research societies and industry representatives from around the world - share a common vision of a world without osteoporotic fractures. Launched in 1998 with the merger of the European Foundation for Osteoporosis (EFFO, founded in 1987) and the International Federation of Societies on Skeletal Diseases, IOF now represents 195 societies in 92 locations. www.iofbonehealth.org

International Osteoporosis Foundation

Related Osteoporosis Articles from Brightsurf:

New opportunities for detecting osteoporosis
Osteoporosis can be detected through low dose computed tomography (LDCT) imaging tests performed for lung cancer screening or other purposes.

Oxytocin can help prevent osteoporosis
In a laboratory experiment with rats, Brazilian researchers succeeded in reversing natural processes associated with aging that lead to loss of bone density and strength.

New strategy against osteoporosis
An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.

New review on management of osteoporosis in premenopausal women
An IOF and ECTS Working Group have published an updated review of literature published after 2017 on premenopausal osteoporosis.

Cardiac CT can double as osteoporosis test
Cardiac CT exams performed to assess heart health also provide an effective way to screen for osteoporosis, potentially speeding treatment to the previously undiagnosed, according to a new study.

Osteoporosis treatment may also protect against pneumonia
A recent study published in the Journal of Bone and Mineral Research found that nitrogen-containing bisphosphonates (N-BPs) such as alendronate, which are widely used to treat postmenopausal osteoporosis, are linked with lower risks of pneumonia and of dying from pneumonia.

New pharmaceutical target reverses osteoporosis in mice
Biomedical engineers at Duke University have discovered that an adenosine receptor called A2B can be pharmaceutically activated to reverse bone degradation caused by osteoporosis in mouse models of the disease.

A link between mitochondrial damage and osteoporosis
In healthy people, a tightly controlled process balances out the activity of osteoblasts, which build bone, and osteoclasts, which break it down.

Many stroke patients not screened for osteoporosis, despite known risks
Many stroke survivors have an increased risk of osteoporosis, falls or breaks when compared to healthy people.

Many postmenopausal women do not receive treatment for osteoporosis
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society.

Read More: Osteoporosis News and Osteoporosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.